Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Suhani Sinha, Sonali, Vandana Garg, Sonia Thapa, Shashank Singh, Mahima Chauhan, Rohit Dutt & Rahul Pratap Singh. (2022) Empagliflozin containing chitosan-alginate nanoparticles in orodispersible film: preparation, characterization, pharmacokinetic evaluation and its in-vitro anticancer activity. Drug Development and Industrial Pharmacy 48:7, pages 279-291.
Read now
Read now
Bryce C Simes & Gordon G MacGregor. (2019) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. Diabetes, Metabolic Syndrome and Obesity 12, pages 2125-2136.
Read now
Read now
Vani P Sanon, Shalin Patel, Saurabh Sanon, Ruben Rodriguez, Son V Pham & Robert Chilton. (2017) Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. Therapeutics and Clinical Risk Management 13, pages 603-611.
Read now
Read now
Sayf A Yassin & Vanita R Aroda. (2017) Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale. Drug Design, Development and Therapy 11, pages 923-937.
Read now
Read now
Hala Ahmadieh, Nisrine Ghazal & Sami T Azar. (2017) Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 10, pages 161-167.
Read now
Read now
Paola Fioretto & Angelo Avogaro. (2017) Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 517-527.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2017) Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:2, pages 211-223.
Read now
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2016) Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:11, pages 1367-1380.
Read now
Read now
Masatoshi Hasegawa, Yukihiro Chino, Nobuko Horiuchi, Kenji Hachiuma, Masahiro Ishida, Yoshiki Fukasawa, Yasuhiro Nakai & Jun-ichi Yamaguchi. (2015) Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent. Xenobiotica 45:12, pages 1105-1115.
Read now
Read now
Giorgio Gentile, Daniela Mastroluca, Piero Ruggenenti & Giuseppe Remuzzi. (2014) Novel effective drugs for diabetic kidney disease? or not?. Expert Opinion on Emerging Drugs 19:4, pages 571-601.
Read now
Read now
André J Scheen. (2014) Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opinion on Drug Metabolism & Toxicology 10:5, pages 647-663.
Read now
Read now
Articles from other publishers (54)
Tania Sundra, Guy Lester, Gabriele Rossi & David Rendle. (2023) Sodium–glucose cotransporter 2 inhibitors in horses—Magic bullet or latest fad?. Equine Veterinary Journal 55:4, pages 559-562.
Crossref
Crossref
Tania Sundra, Erin Kelty & David Rendle. (2022) Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: A case series. Equine Veterinary Education 35:6, pages 311-320.
Crossref
Crossref
Xianghong Wang, Niujian Wu, Chuanchuan Sun, Donghua Jin & Hongyun Lu. (2023) Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome 15:1.
Crossref
Crossref
Eman A. Bahgat, Hisham Hashem, Hanaa Saleh, Ebraam B. Kamel & Maya S. Eissa. (2023) HPLC-DAD technique for the quantification of a recently approved anti-diabetic triple combination along with two toxic official impurities: Toxicity confirmation aided by molecular docking application. BMC Chemistry 17:1.
Crossref
Crossref
Manuel A. Cornejo, Eira Jardines, Akira Nishiyama, Daisuke Nakano & Rudy M. Ortiz. (2023) Simultaneous SGLT2 inhibition and caloric restriction improves insulin resistance and kidney function in OLETF rats. Molecular and Cellular Endocrinology 560, pages 111811.
Crossref
Crossref
Despina Sanoudou, Christos S. Mantzoros & Michael A. Hill. (2022) Sodium-glucose cotransporter-2 inhibitors: A treatment option for recurrent vasovagal syndrome?. Metabolism 137, pages 155309.
Crossref
Crossref
Suiyuan Hu, Chu Lin, Xiaoling Cai, Xingyun Zhu, Fang Lv, Wenjia Yang & Linong Ji. (2022) Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology 13.
Crossref
Crossref
Kentaro Ejiri, Toru Miyoshi, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano, Atsushi Takaishi, Hironobu Toda, Seiji Namba, Yoichi Nakamura, Satoshi Akagi, Satoru Sakuragi, Taro Minagawa, Yusuke Kawai, Nobuhiro Nishii, Soichiro Fuke, Masaki Yoshikawa, Kazufumi Nakamura, Hiroshi Ito, Kentaro Ejiri, Toru Miyoshi, Kazufumi Nakamura, Hiroshi Ito, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano, Atsushi Takaishi, Hironobu Toda, Seiji Namba, Yoichi Nakamura, Satoshi Akagi, Satoru Sakuragi, Taro Minagawa, Yusuke Kawai, Nobuhiro Nishii, Tetsuya Sato, Soichiro Fuke, Masaki Yoshikawa, Hiroyasu Sugiyama, Michio Imai, Naoki Gotoh, Tomonori Segawa, Toshiyuki Noda & Masatoshi Koshiji. (2022) Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. Scientific Reports 12:1.
Crossref
Crossref
Theocharis Koufakis, Symeon Metallidis, Pantelis Zebekakis & Kalliopi Kotsa. (2021) Intestinal SGLT1 as a therapeutic target in COVID‐19‐related diabetes: A “two‐edged sword” hypothesis. British Journal of Clinical Pharmacology 87:10, pages 3643-3646.
Crossref
Crossref
Adeboye Olakunle Bamgboye, Isaac Oluwadamilare Oni & Andrew Collier. (2020) Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. European Journal of Clinical Pharmacology 77:5, pages 651-657.
Crossref
Crossref
Charalampos I. Liakos, Dimitrios P. Papadopoulos, Elias A. Sanidas, Maria I. Markou, Erifili E. Hatziagelaki, Charalampos A. Grassos, Maria L. Velliou & John D. Barbetseas. (2020) Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors). American Journal of Cardiovascular Drugs 21:2, pages 123-137.
Crossref
Crossref
Najeeb Shah, Mohammed Altigani Abdalla, Harshal Deshmukh & Thozhukat Sathyapalan. (2021) Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Therapeutic Advances in Endocrinology and Metabolism 12, pages 204201882110421.
Crossref
Crossref
Theocharis Koufakis, Nikolaos Papanas, George Dimitriadis, Pantelis Zebekakis & Kalliopi Kotsa. (2020)
Interpreting the results of the
VERTIS‐CV
trial: Is this the end of the “class effect” perspective?
. Journal of Diabetes 12:12, pages 942-945.
Crossref
Crossref
Xiangyang Liu, Chaofei Xu, Linxin Xu, Xiaoyu Li, Hongxi Sun, Mei Xue, Ting Li, Xiaochen Yu, Bei Sun & Liming Chen. (2020) Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway. Metabolism 111, pages 154334.
Crossref
Crossref
Kentaro Ejiri, Toru Miyoshi, Hajime Kihara, Yoshiki Hata, Toshihiko Nagano, Atsushi Takaishi, Hironobu Toda, Seiji Nanba, Yoichi Nakamura, Satoshi Akagi, Satoru Sakuragi, Taro Minagawa, Yusuke Kawai, Nobuhiro Nishii, Soichiro Fuke, Masaki Yoshikawa, Kazufumi Nakamura, Hiroshi Ito, Tetsuya Sato, Hiroyasu Sugiyama, Michio Imai, Naoki Gotoh, Tomonori Segawa, Toshiyuki Noda & Masatoshi Koshiji. (2020) Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus. Journal of the American Heart Association 9:16.
Crossref
Crossref
Ryoichi Ishibashi, Yoko Takatsuna, Masaya Koshizaka, Tomoaki Tatsumi, Sho Takahashi, Kengo Nagashima, Noriko Asaumi, Miyuki Arai, Fumio Shimada, Kaori Tachibana, Yoshihiro Watanabe, Ko Ishikawa, Akiko Hoshino, Kyohei Yamamoto, Mariko Kubota-Taniai, Takafumi Mayama, Shuichi Yamamoto & Koutaro Yokote. (2020) Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Therapy 11:8, pages 1891-1905.
Crossref
Crossref
T. S. Panevin, M. S. Eliseev, M. V. Shestakova & E. L. Nasonov. (2020) Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Terapevticheskii arkhiv 92:5, pages 110-118.
Crossref
Crossref
Canan ERSOY. (2020) SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control. Turkish Journal of Internal Medicine 2:1, pages 1-4.
Crossref
Crossref
Belma Turan. 2020. Biochemistry of Cardiovascular Dysfunction in Obesity. Biochemistry of Cardiovascular Dysfunction in Obesity
125
144
.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi & Andrea Giaccari. (2019) Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Priyanka A. Shah, Pranav S. Shrivastav, Vinay Sharma & Manish S. Yadav. (2019) Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 175, pages 112790.
Crossref
Crossref
Oğuz Akkuş, Gamze Akkuş & Onur Kaypaklı. (2019) The Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitus. Endocrine, Metabolic & Immune Disorders - Drug Targets 19:2, pages 207-213.
Crossref
Crossref
Yajing Zhang, Huazhuo Ban, Runan Yu, Zhijian Wang & Dayong Zhang. (2018) Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents. Future Medicinal Chemistry 10:10, pages 1261-1276.
Crossref
Crossref
Baptist Gallwitz. (2018) The Cardiovascular Benefits Associated with the Use of Sodium-glucose Cotransporter 2 Inhibitors – Real-world Data. European Endocrinology 14:1, pages 17.
Crossref
Crossref
Tatsuhiko Urakami, Midori Yoda, Kei Yoshida, Yusuke Mine, Masako Aoki & Junichi Suzuki. (2018) Renal glucosuria in schoolchildren: Clinical characteristics. Pediatrics International 60:1, pages 35-40.
Crossref
Crossref
Hala AhmadiehSami Azar. (2017) Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus. Diabetes Technology & Therapeutics 19:9, pages 507-512.
Crossref
Crossref
Hermann Koepsell. (2017) The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer. Pharmacology & Therapeutics 170, pages 148-165.
Crossref
Crossref
Volker Vallon & Scott C. Thomson. (2016) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:2, pages 215-225.
Crossref
Crossref
G. Bebernitz. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
491
511
.
Tushar Madaan, Mohd. Akhtar & Abul Kalam Najmi. (2016) Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective. European Journal of Pharmaceutical Sciences 93, pages 244-252.
Crossref
Crossref
Naveed Sattar, James McLaren, S?ren L. Kristensen, David Preiss & John J. McMurray. (2016) SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 59:7, pages 1333-1339.
Crossref
Crossref
Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux & Po Sing Leung. (2016) The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLOS ONE 11:1, pages e0147391.
Crossref
Crossref
Paola Fioretto, Andrea Giaccari & Giorgio Sesti. (2015) Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Yuji Kumagai, Tomoko Hasunuma, Soichi Sakai, Hidekazu Ochiai & Yoshishige Samukawa. (2015) Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects. PLOS ONE 10:10, pages e0139873.
Crossref
Crossref
Ele Ferrannini & Ralph A. DeFronzo. (2015) Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal 36:34, pages 2288-2296.
Crossref
Crossref
Jinxing Xu, Haoliang Yuan, Ting Ran, Yanmin Zhang, Haichun Liu, Shuai Lu, Xiao Xiong, Anyang Xu, Yulei Jiang, Tao Lu & Yadong Chen. (2015) A selectivity study of sodium-dependent glucose cotransporter 2/sodium-dependent glucose cotransporter 1 inhibitors by molecular modeling. Journal of Molecular Recognition 28:8, pages 467-479.
Crossref
Crossref
Manuel Puig-Domingo & Silvia Pellitero. (2015) Nuevos agentes terapéuticos para la diabetes tipo 2. Medicina Clínica 144:12, pages 560-565.
Crossref
Crossref
Manuel Puig-Domingo & Silvia Pellitero. (2015) New therapies for type 2 diabetes mellitus. Medicina Clínica (English Edition) 144:12, pages 560-565.
Crossref
Crossref
Julio Rosenstock, William T. Cefalu, Pablo Lapuerta, Brian Zambrowicz, Ike Ogbaa, Phillip Banks & Arthur Sands. (2015) Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy. Diabetes Care 38:3, pages 431-438.
Crossref
Crossref
William N. Washburn. 2015. Successful Drug Discovery. Successful Drug Discovery
87
112
.
Volker Vallon. (2015) The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus. Annual Review of Medicine 66:1, pages 255-270.
Crossref
Crossref
Yasong Lu, Steven C. Griffen, David W. Boulton & Tarek A. Leil. (2014) Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Frontiers in Pharmacology 5.
Crossref
Crossref
Akiko Mizuno-Yasuhira, Yasuhiro Nakai, Emi Gunji, Saeko Uchida, Teisuke Takahashi, Kohnosuke Kinoshita, Shigeji Jingu, Soichi Sakai, Yoshishige Samukawa & Jun-ichi Yamaguchi. (2014) A Strategy for Assessing Potential Drug-Drug Interactions of a Concomitant Agent against a Drug Absorbed via an Intestinal Transporter in Humans. Drug Metabolism and Disposition 42:9, pages 1456-1465.
Crossref
Crossref
Stefan Engeli & Jens Jordan. (2014) Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors. Current Opinion in Nephrology and Hypertension 23:5, pages 468-472.
Crossref
Crossref
Luca De Nicola, Francis B. Gabbai, Maria Elena Liberti, Adelia Sagliocca, Giuseppe Conte & Roberto Minutolo. (2014) Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes. American Journal of Kidney Diseases 64:1, pages 16-24.
Crossref
Crossref
Raewyn M. Poole & Jennifer E. Prossler. (2014) Tofogliflozin: First Global Approval. Drugs 74:8, pages 939-944.
Crossref
Crossref
Ralph A. DeFronzo, Curtis L. Triplitt, Muhammad Abdul-Ghani & Eugenio Cersosimo. (2014) Novel Agents for the Treatment of Type 2 Diabetes. Diabetes Spectrum 27:2, pages 100-112.
Crossref
Crossref
William N. Washburn. 2014.
363
382
.
Alan Braem, Prashant P. Deshpande, Bruce A. Ellsworth & William N. Washburn. 2014. Carbohydrates as Drugs. Carbohydrates as Drugs
73
94
.
T Nagata, T Fukuzawa, M Takeda, M Fukazawa, T Mori, T Nihei, K Honda, Y Suzuki & Y Kawabe. (2013)
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in
db/db
mice
. British Journal of Pharmacology 170:3, pages 519-531.
Crossref
Crossref
Mark Tirmenstein, Thomas E. Dorr, Evan B. Janovitz, Deborah Hagan, Lynn M. Abell, Joelle M. Onorato, Jean M. Whaley, Michael J. Graziano & Timothy P. Reilly. (2013) Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor. International Journal of Toxicology 32:5, pages 336-350.
Crossref
Crossref
Brian Zambrowicz, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Kristi A. Boehm, Dennis Ruff, David Powell & Arthur Sands. (2013) Effects of LX4211, a Dual Sodium-Dependent Glucose Cotransporters 1 and 2 Inhibitor, on Postprandial Glucose, Insulin, Glucagon-like Peptide 1, and Peptide Tyrosine Tyrosine in a Dose-Timing Study in Healthy Subjects. Clinical Therapeutics 35:8, pages 1162-1173.e8.
Crossref
Crossref
Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth & J. Robert Merritt. 2013.
471
546
.
Manuel Alejandro Cornejo, Akira Nishiyama, Daisuke Nakano & Rudy Ortiz. (2022) Simultaneous SGLT2 Inhibition and Caloric Restriction Improves Insulin Resistance and Kidney Function in OLETF Rats. SSRN Electronic Journal.
Crossref
Crossref